62011-40-9

Upstream product

• 38780-40-4 {(1R,2R)-cyclohexane-1,2-diamine}dichloridoplatinum(II) 
• 66845-32-7 trans-cyclohexamethylene diaminediiodoplatinum(II) 
• 61848-66-6 (1R,2R)-1,2-diaminocyclohexanedichloroplatinum(II) 
• 7732-18-5 water 
• 61848-66-6 cis-dichloro-(cis-1,2-diaminocyclohexane)platinum(II) 

Downstream Products

• 111556-07-1 Pt(R,R-Dach)(N-CH₂Ph*IDA) 
• 111556-05-9 Pt(R,R-DACH)(N-EtOH*IDA) 
• 96322-20-2 ((CH₂)4CHCCOO)2Pt(NH₂(C₆H₁₀)NH₂) 
• 96322-13-3 bis(cyclohexanecarboxylato)(1,2-diaminocyclohexane)platinum(II) 
• 99144-84-0 ((C₆H₁₁)CH₂COO)2Pt(NH₂(C₆H₁₀)NH₂) 

Relevant academic research and scientific papers

Translocation of platinum anticancer drugs by human copper ATPases ATP7A and ATP7B

Cisplatin, carboplatin, and oxaliplatin are widely used anticancer drugs. Their efficacy is strongly reduced by development of cell resistance. Down-regulation of CTR1 and up-regulation of the Cu-ATPases, ATP7A and ATP7B, have been associated to augmented drug resistance. To gain information on translocation of Pt drugs by human Cu- ATPases, we performed electrical measurements on the COS- 1 cell microsomal fraction, enriched with recombinant ATP7A, ATP7B, and selected mutants, and adsorbed on a solid supported membrane. The experimental results indicate that Pt drugs activate Cu-ATPases and undergo ATP-dependent translocation in a fashion similar to that of Cu. We then used NMR spectroscopy and ESI-MS to determine the binding mode of these drugs to the first N-terminal metal-binding domain of ATP7A (Mnk1).

Metal-polysaccharide conjugates: compositions, synthesis and methods for cancer therapy

The current disclosure, in one embodiment, includes a polysaccharide conjugate. This conjugate has a polysaccharide and at least one monomeric amino acid having an O-group covalently bound to the polysaccharide. The conjugate also has at least one metal conjugated by the O-group of the amino acid. According to another embodiment, the disclosure provides a method of synthesizing a polysaccharide conjugate by covalently bonding a monomeric amino acid having an O-group to a polysaccharide and by conjugating a metal to the O-group to form a polysaccharide conjugate. According to a third embodiment, the disclosure relates to a method of killing a cancer cell by administering to the cell an effective amount of a polysaccharide conjugate. This conjugate has a polysaccharide and at least one monomeric amino acid having an O-group covalently bound to the polysaccharide. The conjugate also has at least one metal conjugated by the O-group of the amino acid.

Synthesis and characterization of diastereomeric (substituted iminodiacetato) (1,2- diaminocyclohexane)platinum(II) complexes

Novel complexes of the type [Pt(DACH)(N-R·iminodiacetate)], wherein DACH represents (R,S)- and (R,R)- 1,2-diaminocyclohexane and R represents -Me, -EtOH, and -CH2Ph groups, have been prepared, purified, and characterized by spectroscopic techniques (1H, 13C, and 195Pt NMR; MS(FAB); IR) and by the measurement of selected physical properties (pH, pKa, conductivity, and molecular weights). The data are consistent with the formation of two diastereomeric complexes in unequal proportions in which the N-R-iminodiacetate ligand appears to be bonded as a pseudofacial tridentate chelate. One arm of the ligand forms a stable five-membered-ring O,N-chelate while the other arm appears to be involved in ion-pair formation (zwitterion-like) involving the carboxylate anion and the formally positive Pt(II) central metal atom. It has been demonstrated indirectly that an active impurity was present in predictably inactive bulk complexes of the type PtN3O. The need to characterize unequivocally and certify the purity of prospective antitumor complexes is emphasized.